Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, Wegovy does reduce hunger for most people who take it. Semaglutide works by activating GLP-1 receptors in the brain's appetite centres, slowing the speed at which food leaves your stomach and increasing the hormonal signals that tell your body it has eaten enough. In clinical trials, participants reported a meaningful and sustained reduction in how often and how intensely they felt hungry. That said, appetite suppression varies between individuals, and some people notice it more at certain doses or stages of treatment than others. Wegovy is a prescription-only medicine; a GPhC-registered prescriber decides whether it is clinically appropriate for you, and they are the right person to talk to about what to expect from your own appetite changes. If you want to understand what not feeling hungry on Wegovy actually feels like day to day, there is more detail on that experience in our dedicated page.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Hunger is not one single signal. It is a conversation between your gut, your bloodstream and several regions of the brain, particularly the hypothalamus. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating. It travels to the brain and essentially tells it the meal is done. Semaglutide, the active ingredient in Wegovy, mimics this hormone and binds to the same receptors, but it does so far more persistently than the natural version, which is broken down within minutes.
The result is that those receptors receive a steady, prolonged signal: you have eaten, you are full, slow down. The hypothalamus responds by dialling back the drive to seek food. Separately, semaglutide slows gastric emptying, food moves through the stomach more gradually, which sustains the physical sensation of fullness. These two mechanisms compound each other. Many people on Wegovy describe not just reduced hunger but a quieting of food-related thoughts, sometimes called the reduction in wanting to eat even when not physically hungry.
The NHS medicines page for semaglutide confirms that appetite suppression is one of the primary ways the medicine supports weight management. It is worth understanding, though, that the biology works best alongside the reduced-calorie diet and increased activity that form part of the licensed treatment plan.
For the majority of people, it eases rather than vanishes. In the STEP 1 trial (68 weeks, 2.4 mg semaglutide, nearly 2,000 adults with obesity) participants lost an average of around 15% of body weight, an outcome that reflects sustained appetite change rather than complete hunger elimination. Researchers measured appetite scores throughout and found significant reductions, but participants still ate. They just ate less, and felt satisfied sooner.
Some people do experience periods of feeling almost entirely indifferent to food, particularly after a dose increase. Others notice the effect fluctuates week to week. A small group find that hunger returns between doses, usually in the day or two before their next weekly injection. Our page on whether Wegovy can cause hunger covers those patterns in more detail.
The practical implication is that the medicine changes the environment your appetite operates in, it does not override your ability to eat. Knowing that helps you work with the effect rather than being surprised when some hunger does return.
Generally, yes. Wegovy is started at 0.25 mg weekly and the dose is increased in steps, approximately every four weeks, up to the 2.4 mg maintenance dose. The starter dose is primarily about letting your body adjust; noticeable appetite suppression tends to build with each step up. Most people report the clearest effect once they are on or approaching the maintenance dose.
This matters practically. Some people expect dramatic hunger reduction from week one and feel the medicine is not working when it does not arrive immediately. It is more useful to track whether your appetite is gradually quieter across the weeks rather than looking for an overnight switch. Our page on how semaglutide reduces appetite goes into more detail on the dose-response relationship.
There is also now a 7.2 mg pen available following MHRA approval in April 2026, for eligible patients whose prescriber considers it appropriate, this higher maintenance dose may produce a stronger effect. Our Wegovy overview page covers what this means for eligibility and treatment options.
Less hunger does not automatically mean better nutrition. When appetite drops sharply, people sometimes eat too little protein, skip meals that felt unnecessary or find that food now seems unappealing in a way that reduces diet quality. Getting this right matters: adequate protein protects muscle during weight loss, and fibre supports the gut changes that come with slowed gastric emptying.
Keeping your weekly pen in the fridge door is a small habit that makes dose days feel routine, but the bigger habit worth building is structuring what you do eat around protein and vegetables rather than relying on appetite to guide you, because that signal is now quieter by design.
Our page on what to eat on Wegovy is a practical guide to meals and portion approaches that work alongside reduced appetite. For context on the cost of treatment and what is included in a private prescription, our Wegovy pricing page explains how private treatment is structured. And if you have noticed that your appetite comes back unexpectedly on some weeks, this page on Wegovy and hunger returning addresses that directly.
Wegovy is a prescription-only medicine under UK law, which means the right next step is a clinical conversation rather than a self-guided decision. Speak to our prescribers through a free consultation, a GPhC-registered clinician reviews your answers the same day and can talk through what appetite changes are realistic for your situation. You can also read about our full range of weight-loss treatment options or learn more about how nume works before you start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.